Longitudinal natural history of type I spinal muscular atrophy: a critical review
Open Access
- 5 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 15 (1), 1-7
- https://doi.org/10.1186/s13023-020-01356-1
Abstract
Background The advent of new therapies in spinal muscular atrophy (SMA) has highlighted the need to have natural history data for comparison. Natural history studies using structured assessments in type I however are very limited. We identified and reviewed all the existing longitudinal history data in infants with type I SMA first assessed before the age of 7 months with the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). Main text Three longitudinal natural history studies, two performed in the United States and one in Italy, were identified. The different study design of these three studies made it possible for the cumulative dataset to include the full spectrum of severity; from infants with neonatal onset to those with a milder phenotype that were not always included in the individual natural history studies. The cumulative analysis confirmed that, even in a larger cohort, there was never an improvement on the CHOP INTEND over time. This was true for all the infants, irrespective of their age or baseline CHOP INTEND scores. Infants with neonatal onset had low CHOP INTEND scores and a fast decline. The relatively large number of patients allowed us to calculate the rate of progression in subgroups identified according to SMN2 copy number and baseline CHOP INTEND scores. Conclusion A detailed understanding of the existing data is important, as it will be difficult to acquire new systematic longitudinal history data because of the availability of disease modifying therapies. The cumulative findings in this review help to better understand the variability of natural history data in untreated patients and will be of use for comparison to the real world patients treated with the recently approved therapies that have shown encouraging results in clinical trials.Funding Information
- Fondazione Telethon (GSP 13002)
This publication has 21 references indexed in Scilit:
- Stakeholder collaboration for spinal muscular atrophy therapy developmentThe Lancet Neurology, 2017
- Results from a phase 1 study of nusinersen (ISIS-SMN Rx ) in children with spinal muscular atrophyNeurology, 2016
- Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker studyAnnals of Clinical and Translational Neurology, 2016
- Observational study of spinal muscular atrophy type I and implications for clinical trialsNeurology, 2014
- Validation of the Expanded Hammersmith Functional Motor Scale in Spinal Muscular Atrophy Type II and IIIJournal of Child Neurology, 2011
- The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): Test development and reliabilityNeuromuscular Disorders, 2010
- Consensus Statement for Standard of Care in Spinal Muscular AtrophyJournal of Child Neurology, 2007
- Medical Considerations of Long-Term Survival of Werdnig–Hoffmann DiseaseAmerican Journal of Physical Medicine & Rehabilitation, 2007
- Spinal Muscular Atrophy: Survival Pattern and Functional StatusPEDIATRICS, 2004
- Early infantile form of spinal muscular atrophy (Werdnig-Hoffmann disease) with prolonged survival.2002